Nirsevimab MELODY Phase III Trial Met Primary Endpoint of Reducing RSV Lower Respiratory Tract Infections in Healthy Infants

26 April 2021 -- The MELODY Phase III trial for nirsevimab met its primary endpoint of a statistically significant reduction in the incidence of medically attended lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV)...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials